Comparative Pharmacology
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus DENAVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus DENAVIR.
ADEFOVIR DIPIVOXIL vs DENAVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
DENAVIR is a synthetic peptide that inhibits viral replication by preventing the fusion of the viral envelope with the host cell membrane. It specifically targets the HIV-1 envelope glycoprotein gp41, blocking the conformational changes required for membrane fusion.
10 mg orally once daily on an empty stomach.
5 mg applied topically to affected area once daily for 4 weeks.
None Documented
None Documented
Clinical Note
moderateAdefovir dipivoxil + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Clinical Note
moderateAdefovir dipivoxil + Tenofovir disoproxil
"The therapeutic efficacy of Tenofovir disoproxil can be decreased when used in combination with Adefovir dipivoxil."
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Terminal elimination half-life is 2.5–3.5 hours in patients with normal renal function. Prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Renal excretion of unchanged drug accounts for approximately 90% of the administered dose via glomerular filtration and tubular secretion. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
Antiviral
Antiviral